145 related articles for article (PubMed ID: 16010549)
41. Validation and utilization of a TFE3 break-apart FISH assay for Xp11.2 translocation renal cell carcinoma and alveolar soft part sarcoma.
Pradhan D; Roy S; Quiroga-Garza G; Cieply K; Mahaffey AL; Bastacky S; Dhir R; Parwani AV
Diagn Pathol; 2015 Sep; 10():179. PubMed ID: 26415891
[TBL] [Abstract][Full Text] [Related]
42. MDCT findings of renal cell carcinoma associated with Xp11.2 translocation and TFE3 gene fusion and papillary renal cell carcinoma.
Woo S; Kim SY; Lee MS; Moon KC; Kim SH; Cho JY; Kim SH
AJR Am J Roentgenol; 2015 Mar; 204(3):542-9. PubMed ID: 25714283
[TBL] [Abstract][Full Text] [Related]
43. [A case of xp11.2 translocation renal cell carcinoma].
Horie K; Kikuchi M; Miwa K; Minamidate Y; Yokoi S; Nakano M; Deguchi T; Ehara H; Asano N; Hirose Y
Hinyokika Kiyo; 2011 Mar; 57(3):129-33. PubMed ID: 21586884
[TBL] [Abstract][Full Text] [Related]
44. Review of renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with focus on pathobiological aspect.
Kuroda N; Mikami S; Pan CC; Cohen RJ; Hes O; Michal M; Nagashima Y; Tanaka Y; Inoue K; Shuin T; Lee GH
Histol Histopathol; 2012 Feb; 27(2):133-40. PubMed ID: 22207547
[TBL] [Abstract][Full Text] [Related]
45. Role of Mitochondrial DNA Copy Number Alteration in Human Renal Cell Carcinoma.
Lin CS; Lee HT; Lee MH; Pan SC; Ke CY; Chiu AW; Wei YH
Int J Mol Sci; 2016 May; 17(6):. PubMed ID: 27231905
[TBL] [Abstract][Full Text] [Related]
46. Overexpression of cyclin D1, D3, and p21 in an infantile renal carcinoma with Xp11.2 TFE3-gene fusion.
Müller-Höcker J; Babaryka G; Schmid I; Jung A
Pathol Res Pract; 2008; 204(8):589-97. PubMed ID: 18358634
[TBL] [Abstract][Full Text] [Related]
47. Renal cell carcinoma associated with TFE3 gene fusion in an elderly woman.
LaGrange CA; Lele SM; Strup SE
Urology; 2007 Sep; 70(3):590.e11-2. PubMed ID: 17905124
[TBL] [Abstract][Full Text] [Related]
48. PRCC, the commonest TFE3 fusion partner in papillary renal carcinoma is associated with pre-mRNA splicing factors.
Skalsky YM; Ajuh PM; Parker C; Lamond AI; Goodwin G; Cooper CS
Oncogene; 2001 Jan; 20(2):178-87. PubMed ID: 11313942
[TBL] [Abstract][Full Text] [Related]
49. Molecular mechanisms underlying the MiT translocation subgroup of renal cell carcinomas.
Medendorp K; van Groningen JJ; Schepens M; Vreede L; Thijssen J; Schoenmakers EF; van den Hurk WH; Geurts van Kessel A; Kuiper RP
Cytogenet Genome Res; 2007; 118(2-4):157-65. PubMed ID: 18000366
[TBL] [Abstract][Full Text] [Related]
50. Renal cell carcinoma associated with Xp11.2 translocation/TFE3 gene fusions: clinical experience and literature review.
He J; Chen X; Gan W; Zhu B; Fan X; Guo H; Jia R
Future Oncol; 2015; 11(24):3243-52. PubMed ID: 26169997
[TBL] [Abstract][Full Text] [Related]
51. Secondary PSF/TFE3-associated renal cell carcinoma in a child treated for genitourinary rhabdomyosarcoma.
Brassesco MS; Valera ET; Bonilha TA; Scrideli CA; Carvalho de Oliveira J; Pezuk JA; Barros Silva GE; Costa RS; Tone LG
Cancer Genet; 2011 Feb; 204(2):108-10. PubMed ID: 21504709
[TBL] [Abstract][Full Text] [Related]
52. [Renal carcinoma associated with Xp11.2 translocations/TFE3 gene fusions with lymph node metastasis diagnosed after an injury accident: report of a case].
Chen Y; Kang S; Qiu J
Zhonghua Bing Li Xue Za Zhi; 2014 Feb; 43(2):123-4. PubMed ID: 24742576
[No Abstract] [Full Text] [Related]
53. TFE3-renal carcinoma in an adult patient: a case with strong expression of phosphorylated hepatocyte growth factor (HGFR)/Met.
Sagara Y; Miyata Y; Nomata K; Abe K; Eguchi J; Hayashi T; Sakai H; Kanda S; Kanetake H
Pathol Res Pract; 2009; 205(1):57-61. PubMed ID: 18930356
[TBL] [Abstract][Full Text] [Related]
54. PSF/SFPQ is a very common gene fusion partner in TFE3 rearrangement-associated perivascular epithelioid cell tumors (PEComas) and melanotic Xp11 translocation renal cancers: clinicopathologic, immunohistochemical, and molecular characteristics suggesting classification as a distinct entity.
Rao Q; Shen Q; Xia QY; Wang ZY; Liu B; Shi SS; Shi QL; Yin HL; Wu B; Ye SB; Li L; Chen JY; Pan MH; Li Q; Li R; Wang X; Zhang RS; Yu B; Ma HH; Lu ZF; Zhou XJ
Am J Surg Pathol; 2015 Sep; 39(9):1181-96. PubMed ID: 26274027
[TBL] [Abstract][Full Text] [Related]
55. Clinical features of MELAS and its relation with A3243G gene point mutation.
Zhang J; Guo J; Fang W; Jun Q; Shi K
Int J Clin Exp Pathol; 2015; 8(10):13411-5. PubMed ID: 26722549
[TBL] [Abstract][Full Text] [Related]
56. Translocation carcinomas of the kidney after chemotherapy in childhood.
Argani P; Laé M; Ballard ET; Amin M; Manivel C; Hutchinson B; Reuter VE; Ladanyi M
J Clin Oncol; 2006 Apr; 24(10):1529-34. PubMed ID: 16575003
[TBL] [Abstract][Full Text] [Related]
57. Characterization of t(6;11)(p21;q12) in a renal-cell carcinoma of an adult patient.
Pecciarini L; Cangi MG; Lo Cunsolo C; Macri' E; Dal Cin E; Martignoni G; Doglioni C
Genes Chromosomes Cancer; 2007 May; 46(5):419-26. PubMed ID: 17285572
[TBL] [Abstract][Full Text] [Related]
58. Absence of maternal A3243G mtDNA mutation and reversible hyperglycemia in a patient with MELAS syndrome.
Liou CW; Huang CC; Tsai JL; Liu JY; Pang CY; Lee HC; Wang EK; Wei YH
Acta Neurol Scand; 2000 Jan; 101(1):65-9. PubMed ID: 10660156
[TBL] [Abstract][Full Text] [Related]
59. Renal Cell Carcinoma With Chromosome 6p Amplification Including the TFEB Gene: A Novel Mechanism of Tumor Pathogenesis?
Williamson SR; Grignon DJ; Cheng L; Favazza L; Gondim DD; Carskadon S; Gupta NS; Chitale DA; Kalyana-Sundaram S; Palanisamy N
Am J Surg Pathol; 2017 Mar; 41(3):287-298. PubMed ID: 28009604
[TBL] [Abstract][Full Text] [Related]
60. Xp11 translocation carcinoma of the kidney presenting with multilocular cystic renal cell carcinoma-like features.
Suzigan S; Drut R; Faria P; Argani P; De Marzo AM; Barbosa RN; Mello Denadai ER; Martins-Filho J; Martucci RC; Bauab T
Int J Surg Pathol; 2007 Apr; 15(2):199-203. PubMed ID: 17478783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
